@beltwayboyz Higgins is playing with Nico as his WR1 while burden has no WR1 veteran competition. Hes definitely bound to have a better year statistically but Higgins is the bigger better NFL WR
@beltwayboyz Give it a few years you’ll understand. One is a hard worker the other is a highly talented diva. Higgins will be the better NFL WR. Might not get the shine at first because he’s got Nico, tank, and co around him while there’s not a clear WR1 in Chicago. But Higgins is him.
Too many people spend hundreds chasing the last 5% while ignoring the 95% that actually moves the needle.
Stop looking for a miracle. Start putting in the work.
If you’re running multiple peptides but aren’t doing everything in your power to maximize their potential, your priority isn’t health.
There is no shortcut.
https://t.co/gj4dCu2oxP is an AI driven peptide guide.
Create an account. Track protocols, blood work & body comp. Use resources like the PepTalk AI chat box for any questions, Recon calc, peptide library, & a Reddit style community to connect with people alike. All for $1/month
So no, MOTS-c isn’t a CPAP replacement. But if sleep apnea is beating up your metabolism and mitochondria every night, MOTS-c may be one of the tools that helps your body fight back from the inside out.
One of the biggest pharmaceutical companies in the world is currently fighting the FDA in federal court over Retatrutide.
The outcome could influence exclusivity rights, future competition, and potentially how peptide-based therapies are regulated for years to come.
This case could impact much more than Retatrutide.
If Lilly ultimately wins, the decision could influence future peptide development, exclusivity periods, market competition, pricing, and how similar compounds are regulated moving forward.